Ivabradine Cristers (Ivabradine)

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the heart’s natural pacemaker. By inhibiting this current, the drug slows the spontaneous depolarisation of pacemaker cells, leading to a lower resting heart rate without affecting contractility or blood pressure.

The appropriate dose of Ivabradine Cristers is determined by the prescribing clinician based on the patient’s clinical condition, heart‑rate response, and any concomitant therapies. Dosage adjustments are made according to individual therapeutic goals and safety monitoring.

Safety data for Ivabradine Cristers in pregnancy and lactation are limited. It should only be used when the potential benefit justifies the possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both Ivabradine and beta‑blockers lower heart rate, but Ivabradine does so by selectively inhibiting the If current without affecting myocardial contractility or blood pressure. Beta‑blockers act on adrenergic receptors and have broader cardiovascular effects, which may be advantageous or limiting depending on the patient’s overall condition.

Store Ivabradine Cristers at temperatures below 25 °C in a dry place. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Ivabradine Cristers is taken orally, usually with or without food as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not chewed or crushed, unless otherwise instructed.

The most serious risks include severe bradycardia, symptomatic hypotension, atrial fibrillation, and rare visual disturbances that may lead to persistent vision loss. Patients should be monitored for these events, especially during dose initiation and when combined with other heart‑rate‑lowering agents.

Ivabradine Cristers is contraindicated in patients with severe hepatic impairment, acute decompensated heart failure, sick sinus syndrome, or a resting heart rate below the recommended threshold. It should also be avoided in individuals taking strong CYP3A4 inhibitors or other medications that could cause excessive bradycardia.